Anakinra
- Atc Codes:L04AC03
- CAS Codes:143090-92-0
- PHARMGKB ID:143090-92-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Kineret; Czech Republic: Kineret; Denmark: Kineret; Estonia: Kineret; Finland: Kineret; France: Kineret; Germany: Kineret; Greece: Kineret; Hungary: Kineret; Ireland: Kineret; Italy: Kineret; Latvia: Kineret; Lithuania: Kineret; Luxembourg: Kineret; Malta: Kineret; Netherlands: Kineret; Poland: Kineret; Portugal: Kineret; Romania: Kineret; Slovakia: Kineret; Slovenia: Kineret; Spain: Kineret; Sweden: Kineret; UK: Kineret.
North America
Canada: Kineret; USA: Kineret.
Drug combinations
Chemistry
Anakinra: C~759~H~1186~N~208~O~232~S~10~. Mw: 17258.01. (1) Interleukin 1 receptor antagonist (human isoform x reduced), N^2^-L-methionyl-; (2) N^2^-L-Methionylinterleukin 1 receptor antagonist (human isoform x reduced). CAS-143090-92-0 (1994).
Pharmacologic Category
Biologic Response Modifiers. Disease-modifying Antirheumatic Drugs. Interleukin 1 Receptor Antagonist. (ATC-Code: L04AC03).
Mechanism of action
Antagonist of the interleukin-1 (IL~1~) receptor.
Therapeutic use
Treatment of rheumatoid arthritis in adults.
Pregnancy and lactiation implications
There are no controlled trials in pregnant women. Use with caution during lactation.
Unlabeled use
Contraindications
Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation. Active infections (chronic or local).
Warnings and precautions
May cause hypersensitivity, anaphylaxis, or anaphylactoid reactions. Caution should be exercised when used in history of new/recurrent infections, with conditions that predispose to infections, or with chronic, latent, or localized infections (if a serious infection develops, therapy should be discontinued). Use may affect defenses against malignancies. Use with caution in asthma (risk of serious infection), in hematologic abnormalities (decreases in hematologic parameters), or in renal impairment. If possible, should not be used in combination with tumor necrosis factor antagonists. Use caution in the elderly. Use is not recommended in children. Live vaccines should not be given concurrently. The packaging (needle cover) contains latex.